Dementia vs Alzheimer's Disease — Clinical Trial Comparison
Dementia
Umbrella term for cognitive decline syndromes
VS
Alzheimer's Disease
Most common cause (60–70% of dementia)
Dementia is not a specific disease — it describes a set of symptoms affecting memory, thinking, and social abilities. Alzheimer's disease is the most common cause of dementia, but vascular dementia, Lewy body dementia, and frontotemporal dementia each have their own trial landscape, treatment approaches, and research priorities.
Key Differences at a Glance
| Feature | Dementia (All Types) | Alzheimer's Disease |
|---|---|---|
| Definition | Syndrome of cognitive decline severe enough to interfere with daily life | Specific neurodegenerative disease with amyloid plaques and tau tangles |
| UK prevalence | ~944,000 people living with dementia | ~600,000 of those have Alzheimer's-type dementia |
| Types included | Alzheimer's, vascular, Lewy body, frontotemporal, mixed, and others | Alzheimer's only (sporadic and familial/early-onset) |
| Key pathology | Varies by type (vascular damage, Lewy bodies, TDP-43, etc.) | Amyloid-beta plaques, neurofibrillary tau tangles |
| Typical onset | Varies — some types in 50s–60s (FTD), most over 65 | Usually over 65 (early-onset <65 in ~5% of cases) |
| NICE treatments | Cholinesterase inhibitors (Alzheimer's and Lewy body), memantine | Donepezil, rivastigmine, galantamine, memantine |
Clinical Trial Availability
| Trial Aspect | Dementia (All Types) | Alzheimer's Disease |
|---|---|---|
| UK trials actively recruiting | 80–120 studies (all dementia types) | 50–80 studies (Alzheimer's-specific) |
| Most common trial phase | Phase 2–3 | Phase 1–3 (including prevention) |
| Top interventions tested | Cognitive training, lifestyle interventions, caregiver support, disease-modifying therapies by type | Anti-amyloid antibodies, tau-targeted therapies, neuroinflammation modulators, lifestyle prevention |
| Prevention trials | Growing (midlife risk factor modification) | Major category (amyloid removal before symptoms, APOE4-targeted prevention) |
| Early detection trials | Blood biomarkers, digital cognitive testing | Blood amyloid/tau tests, PET imaging, CSF biomarkers |
| Non-pharmacological trials | Major category (music therapy, exercise, cognitive rehab) | Significant (diet, exercise, cognitive training, sleep) |
Exciting Emerging Treatments
Alzheimer's Disease Trials
- Anti-amyloid antibodies (lecanemab, donanemab) — slowing cognitive decline by clearing amyloid plaques
- Tau-targeted therapies — anti-tau antibodies and aggregation inhibitors
- Blood-based biomarker screening — replacing expensive PET scans with simple blood tests
- APOE4-targeted gene therapy — addressing the strongest genetic risk factor
- Neuroinflammation modulators — targeting the brain's immune response
- Combination approaches — amyloid + tau + lifestyle multi-domain interventions
Other Dementia Type Trials
- Vascular dementia: intensive blood pressure management, cerebrovascular protection agents
- Lewy body dementia: enhanced cholinesterase inhibitor protocols, novel neuroleptic-sparing agents
- Frontotemporal dementia: tau and TDP-43 targeted therapies, antisense oligonucleotides
- Mixed dementia: multi-target approaches addressing both vascular and neurodegenerative pathology
- Digital cognitive interventions: app-based cognitive training and remote monitoring
💡 Concerned about a family history? Prevention trials need you
If you have a parent or sibling with Alzheimer's, especially if diagnosed under 65, you may be eligible for prevention trials. The UK's Dementia Platform and international studies like AHEAD 3-45 are enrolling people with elevated genetic risk or early biomarker changes — before any symptoms appear. Early detection blood tests are making this easier than ever.
Eligibility Differences
Dementia Trial Criteria
- Specific dementia type must be diagnosed — mixed diagnoses may complicate eligibility
- MMSE or MoCA score determines severity (mild 24–30, moderate 10–23, severe <10)
- Brain imaging (MRI) usually required to confirm type and exclude other causes
- Study partner/caregiver involvement often mandatory for monitoring
- Capacity to consent may be required (some trials accept consultee consent)
Alzheimer's-Specific Trial Criteria
- Amyloid biomarker confirmation (PET scan, CSF, or blood test) increasingly required
- Early-onset (<65) vs late-onset categories — some trials target specific age groups
- Mild cognitive impairment (MCI) due to Alzheimer's is a distinct trial population
- Prevention trials may require APOE4 genotype or family history criteria
- Cholinesterase inhibitor stable dose often required before enrolment
🧩 Dementia Trials
Find actively recruiting dementia clinical trials across the UK
View Dementia Trials🧠 Alzheimer's Trials
Find actively recruiting Alzheimer's disease clinical trials across the UK
View Alzheimer's Trials